Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
Autore principale: | Flora, Sanzida Alam |
---|---|
Altri autori: | Azam, Faruque |
Natura: | Tesi |
Lingua: | English |
Pubblicazione: |
Brac University
2024
|
Soggetti: | |
Accesso online: | http://hdl.handle.net/10361/23693 |
Documenti analoghi
-
A review on Bruton's Tyrosine Kinase inhibitors to outline the scopes of further advancements in the treatment of cancer
di: Khan, Muidul Hasan
Pubblicazione: (2024) -
Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
di: Paul, Pulock
Pubblicazione: (2024) -
Impact of treatment size and therapy type in phase II clinical trials of non-small cell lung cancer
di: Rahman, Tasnim
Pubblicazione: (2024) -
A review on cyclin-dependent kinase 7 (CDK7) Inhibitors as anticancer agents
di: Sorno, Rubina Haque
Pubblicazione: (2024) -
Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
di: Hoque, Ismoth Ara
Pubblicazione: (2024)